Systemic Lupus Erythematosus

Research results shows that while overall hospitalization for SLE flare decreased, it increased among African American patients.

Dr. Jing Cui speaks about how she examined lifestyle and environmental factors as well as genetic risk to assess risk of systemic lupus erythematosus.

In this interview, Dr. Edigin speaks about his longitudinal trend analysis that showed a decrease in SLE flare hospitalizations over the last 20 years.

“Systemic lupus erythematosus is a chronic inflammatory autoimmune disease where a variety of organ complications contribute to an increased risk of premature mortality,” investigators stated.

Comprehensive insight on the treatment armamentarium for systemic lupus erythematous and nuances in selecting optimal therapy.

Approximately a third of systemic lupus erythematosus patients experience ocular involvement, which may be linked to disease pathophysiology.

An overview of systemic lupus erythematous including possible causes, prevalence, symptomology, diagnosis, and the goals of therapy.

Investigators analyzed the potential beneficial effect of hydroxychloroquine to prevent COVID-19 infection in patients with rheumatic disease.

Veena Joy, MS, discusses Thermo Scientific’s recent FDA approval of their EliA SmDP-S test, which aides in the diagnosis of Systemic Lupus Erythematosus (SLE).

Results show a significantly higher risk of death and combined poor outcomes compared with patients without lupus and both with and without other comorbidities.

The risk of developing systemic lupus erythematosus (SLE) was reduced by 19% with every increase in a healthy lifestyle index score (HLIS). The risk of dsDNA positive SLE reduced 22% with the addition of each healthy behavior. Those with genetic risk factors may be able to reduce their risk of SLE diagnosis by almost 50% with adherence to healthy lifestyle behaviors.

Richard Furie, MD, discusses the recent FDA approval of anifrolumab-fnia for the treatment of patients with systemic lupus.

Researchers call for greater research on the relationship between PTSD and autoimmune diseases in Medicaid patients after finding a troubling association.

The US Food and Drug Administration (FDA) announced the approval of anifrolumab-fnia (Saphnelo™) for the treatment of moderate to severe systemic lupus erythematosus.

Patients with systemic lupus erythematosus presented more cardiovascular autonomic neuropathy, along with impaired health-related quality of life and parasympathetic function, when compared with a control cohort.

The painTRAINER program included 8 weekly modules, in addition to coping skill activities, in which investigators measured outcomes including the Pain Catastrophizing Scale, pain interference, physical function, anxiety and depression, fatigue, and sleep disturbances.

Glucocorticoid withdrawal over a prolonged period of time did not increase clinical flares or damage for patients with inactive systemic lupus erythematosus.

Research indicates that patients with autoimmune rheumatic diseases (AIRD) did not differ from the general population in terms of protective antibody responses against COVID-19.

A higher proportion of patients with immune-mediated diseases experienced ≥1 thromboembolic events at baseline compared to those without an IMD.

Richard Furie, MD, explains the safety and efficacy of BIIB059 for patients with systemic lupus erythematosus (SLE), the study design and background on his upcoming SLE study, and Biogen’s ongoing commitment to including underrepresented groups in its clinical trials.

Eric Morand, MD, PhD, explains why rheumatologists failing in lupus while succeeding so spectacularly in diseases like rheumatoid arthritis and what needs to change.

An expert rheumatologist shares key insights into common causes, typical presentation, and differential diagnosis of systemic lupus erythematous (SLE) and idiopathic inflammatory myopathies.

As systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS) can cause complications during pregnancy, investigators believe it is imperative that women follow the clinical practice guidelines and receive multidisciplinary counseling before trying to conceive.

Poorer results were associated with lower socioeconomic status (SES) and not being able to access telehealth, which emphasizes the need for access to healthcare and attention to vulnerable populations, such as those with rheumatic diseases, during the pandemic.

While further studies are needed, the results indicate that resolving the SDoH issues, via programs like the iCMP, may decrease healthcare costs while equalizing care and outcomes for both patients with SLE and those with complex chronic conditions in general.